We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+55.49%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$139M
Cap. Flow
+$59.2M
Cap. Flow %
16.67%
Top 10 Hldgs %
32.72%
Holding
89
New
23
Increased
24
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$11.2M
2
EW icon
Edwards Lifesciences
EW
+$8.53M
3
DHR icon
Danaher
DHR
+$8.09M
4
ABBV icon
AbbVie
ABBV
+$6.6M
5
CTLT
CATALENT, INC.
CTLT
+$6.45M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.19M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.77M
4
ISRG icon
Intuitive Surgical
ISRG
+$4.49M
5
SDGR icon
Schrodinger
SDGR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Technology 0.89%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
76
Syndax Pharmaceuticals
SNDX
$1.77B
$445K 0.13%
+30,000
New +$457K
APYX icon
77
Apyx Medical
APYX
$126M
$391K 0.11%
70,497
+35,000
+99% +$145K
MRNS
78
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$254K 0.07%
+25,000
New +$230K
CLPT icon
79
ClearPoint Neuro
CLPT
$463M
$89K 0.03%
25,078
– –
HALO icon
80
Halozyme
HALO
$11.6B
– –
-50,466
Closed -$908K
INSP icon
81
Inspire Medical Systems
INSP
$1.68B
– –
-20,000
Closed -$1.21M
ISRG icon
82
Intuitive Surgical
ISRG
$142B
– –
-27,210
Closed -$4.49M
LAB icon
83
Standard BioTools
LAB
$312M
– –
-225,391
Closed -$572K
SAGE
84
DELISTED
Sage Therapeutics
SAGE
– –
-75,000
Closed -$2.15M
YARW
85
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
– –
-113
Closed -$1.09M
RCM
86
DELISTED
R1 RCM Inc. Common Stock
RCM
– –
-86,492
Closed -$786K
RETA
87
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
– –
-5,027
Closed -$726K
XENT
88
DELISTED
Intersect ENT, Inc
XENT
– –
-165,923
Closed -$1.97M
MNTA
89
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-175,453
Closed -$4.77M
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Parkman Healthcare Partners held 89 positions worth $355M, up 64% from $216M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners deployed $59.2M of net new capital in Q2 2020, opening 23 new positions and adding to 24 existing holdings. Its largest new stake was Humana: 30,000 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $7.1M trimmed.

  • Parkman Healthcare Partners's largest Q2 2020 buy was Humana: 30,000 shares worth $11.6M.
  • Parkman Healthcare Partners added most to GenMark Diagnostics, Inc in Q2 2020, an estimated $6.1M increase.
  • Parkman Healthcare Partners's biggest Q2 2020 reduction was Merck, cutting an estimated $7.1M.
  • Parkman Healthcare Partners fully exited Momenta Pharmaceuticals, Inc. in Q2 2020, selling an estimated $4.77M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $355M portfolio in Q2 2020.
  • Parkman Healthcare Partners opened 23 new positions and closed 10 in Q2 2020.
  • Parkman Healthcare Partners's portfolio value rose 64% quarter-over-quarter to $355M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2020, filed 13 Aug 2020.